Company
Company Overview
Wellthera Co., Ltd. develops the innovative drug delivery technology BUS-DDS to overcome drug delivery barriers in difficult-to-treat diseases.
The Company advances therapeutic options in areas with limited drug access, including pancreatic cancer and central nervous system disorders, based on collaborative research with Teikyo University.
Established
December 19th, 2018
CEO
Kazuo Maruyama, Ph.D.
Professor Emeritus, Teikyo University; developer of the Theranostic Bubble
Directors
Makoto Shimasaki
Tsubame Nishikai
Capital
JPY 30 million
Address
Teikyo University Itabashi Campus
2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
Access
By Train
Approx. 10-minute walk from Jujo Station (JR Saikyo Line)
By Bus
From Oji Station (JR Keihin-Tohoku Line):
Kokusai Kogyo Bus, Platform 6 → bound for Itabashi Station (approx. 10 min), get off at “Teikyo University Hospital”
Kokusai Kogyo Bus, Platform 7 → bound for Akabane Station West Exit (approx. 15 min), get off at “Teikyo University Hospital Front”
Phone
070-2637-8868（Weekday 9:00〜18:00）
Partnership
Wellthera actively promotes partnerships to enhance the therapeutic efficacy of drugs by leveraging its BUS-DDS technology.
Through collaboration with compounds in preclinical or clinical development, as well as approved drugs, we aim to improve clinical utility.
Companies and healthcare professionals interested in collaboration are welcome to contact us.